This article includes discussion of dihydroergotamine, DHE, and Migranal. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.
Historical note and terminology
Ergotamine, originally derived from a rye fungus (Claviceps purpurea) and isolated in 1918, was reported to be an effective antimigraine agent in 1925 in Switzerland (Tfelt-Hansen and Koehler 2008). However, absorption of this compound is erratic by oral or rectal routes, and side effects such as nausea, vomiting, and peripheral vasoconstriction are common. Dihydroergotamine mesylate has been used as an acute migraine treatment since 1945, but tolerability of intravenous administration limited its use. Ergotism can result from prolonged, excessive use. The search for a safer compound led to the development of a dehydrogenated derivative of ergotamine, dihydroergotamine as an adrenolytic agent in 1943. This was first available, in the inconvenient form of intramuscular injection, for treatment of acute migraine. Further clinical trials were conducted for dihydroergotamine administration by nasal spray in the early 1990s. The nasal spray was approved by the United States Food and Drug Administration in 1998. There is renewed interest in dihydroergotamine, and the need for nonoral, noninjected delivery is now being pursued further (Silberstein et al 2020).
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.